Pfizer has initiated a large, global Phase III trial to evaluate the efficacy and safety of sunitinib malate, in combination with erlotinib, in previously treated patients with advanced non-small cell lung cancer (NSCLC). Preliminary results from a Phase II study on the safety and tolerability of sunitinib in combination with erlotinib in patients with advanced NSCLC, indicate that adverse events were mild to moderate in severity. Also, two patients experienced a partial response (PR); one...